CA-GLOBALLOGIC
7.12.2021 14:02:19 CET | Business Wire | Press release
GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced availability of technology accelerators that significantly reduce time to market of custom Over-The-Top (OTT) applications by as much as 30 to 50 percent. This is accomplished through the development of advanced solution accelerators for application development and testing across all major mainstream OTT platforms. GlobalLogic delivers this capability through a software engineering team with deep expertise in the end-to-end OTT value chain, which has developed more than 200 complex applications over the past ten years as part of multiple global OTT services rollouts.
OTT Digital Accelerators
The world of streaming applications has become immense and complex. Consumers demand high-quality, immersive viewing experiences from any provider on any device. To satisfy this demand and increase consumer engagement, OTT service providers must develop extremely efficient, native application experiences across multiple platforms, including living room (Smart TV, Streaming Device), mobile, web and gaming environments. Streaming applications must be highly reliable and resilient, to assure content will be available 24/7. And systems must be robust to enable providers to monetize the service. Global rollouts add additional complexity to the entire development process.
Over the last ten years, GlobalLogic has been delivering custom OTT platform application development services for more than 20 streaming platform customers—resulting in the creation of best practice frameworks and accelerators for faster development of OTT services. The GlobalLogic OTT Channel Development Accelerator and TestLab are two such accelerators enabling GlobalLogic customers such as media companies to create exceptionally reliable, immersive experiences for consumers.
The accelerators are platform-agnostic—compatible with the most commonly used consumer streaming services—as well as device-agnostic, supporting gaming consoles, set-top boxes, smartphones, PCs, and tablets. They also support management of multiple devices from a single interface.
OTT Channel Development Accelerator : A customizable media platform that enables the creation of a fully functional, completely branded OTT channel or app from idea to launch-ready in just 2.5 months.1
Key Features and Benefits:
- Common code base for native applications on similar platforms
- Support for all VOD models (AVOD, SVOD, TVOD)
- Advanced, customizable UI/UX features such as unlimited screens or background video
- Versatile monetization options such as in-app purchases, subscription billing, or ad-based services
- Code base owned by client with flexible GlobalLogic engagement models
OTT TestLab Accelerator : A unified infrastructure that schedules automated quality assurance tests on all OTT devices. Clients can test on their own devices, or leverage GlobalLogic’s devices and labs. This is further enhanced by custom, automated test cases for all major platforms and use cases.
Key Features and Benefits:
- Makes testing possible as soon as channel development project begins
- Jump starts continuous integration/continuous delivery (CI/CD) pipelines
- Simple KPI set up and viewing with easy app adjustment capabilities based on results
- Eliminates need to purchase duplicate equipment dedicated to each device
- 3,000+ test devices spanning all major platforms, vendors, use-cases
“The OTT application landscape has grown dramatically larger and more complex over the past few years, and our clients are seeking partners to help navigate it,” said Arun Mukunda, VP and Global Head, Media and Entertainment, GlobalLogic. “Having delivered hundreds of complex OTT applications, GlobalLogic is in a unique position to help our clients rapidly create and launch high quality streaming services on a global scale at a pace never before possible.”
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
1 Approximate time frame based on building and launching a standard app. More complex apps may take longer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005382/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom